These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34040354)

  • 1. Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.
    Perez-Macia V; Martinez-Cortes M; Mesones J; Segura-Trepichio M; Garcia-Fernandez L
    Patient Prefer Adherence; 2021; 15():999-1015. PubMed ID: 34040354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to extended release naltrexone: Patient and treatment characteristics.
    Chang G; Crawford M; Pitts M; Schein AZ; Goodwin K; Enggasser JL
    Am J Addict; 2018 Sep; 27(6):524-530. PubMed ID: 30106489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
    Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K
    J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001867. PubMed ID: 15674887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior.
    Valbrun LP; Zvonarev V
    J Clin Med Res; 2020 Feb; 12(2):41-63. PubMed ID: 32095174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.
    Haber PS; Riordan BC; Winter DT; Barrett L; Saunders J; Hides L; Gullo M; Manning V; Day CA; Bonomo Y; Burns L; Assan R; Curry K; Mooney-Somers J; Demirkol A; Monds L; McDonough M; Baillie AJ; Clark P; Ritter A; Quinn C; Cunningham J; Lintzeris N; Rombouts S; Savic M; Norman A; Reid S; Hutchinson D; Zheng C; Iese Y; Black N; Draper B; Ridley N; Gowing L; Stapinski L; Taye B; Lancaster K; Stjepanović D; Kay-Lambkin F; Jamshidi N; Lubman D; Pastor A; White N; Wilson S; Jaworski AL; Memedovic S; Logge W; Mills K; Seear K; Freeburn B; Lea T; Withall A; Marel C; Boffa J; Roxburgh A; Purcell-Khodr G; Doyle M; Conigrave K; Teesson M; Butler K; Connor J; Morley KC
    Med J Aust; 2021 Oct; 215 Suppl 7():S3-S32. PubMed ID: 34601742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral naltrexone maintenance treatment for opioid dependence.
    Minozzi S; Amato L; Vecchi S; Davoli M; Kirchmayer U; Verster A
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001333. PubMed ID: 16437431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2000; (3):CD001867. PubMed ID: 10908513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.
    Adi Y; Juarez-Garcia A; Wang D; Jowett S; Frew E; Day E; Bayliss S; Roberts T; Burls A
    Health Technol Assess; 2007 Feb; 11(6):iii-iv, 1-85. PubMed ID: 17280624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders.
    Stoner SA; Arenella PB; Hendershot CS
    PLoS One; 2015; 10(4):e0124613. PubMed ID: 25909320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
    Everly JJ; DeFulio A; Koffarnus MN; Leoutsakos JM; Donlin WD; Aklin WM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Addiction; 2011 Jul; 106(7):1309-18. PubMed ID: 21320227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
    Soyka M; Rösner S
    Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of naltrexone in the treatment of alcohol dependence disorder in women].
    Ponce G; Sánchez-García J; Rubio G; Rodríguez-Jiménez R; Jiménez-Arriero MA; Palomo T
    Actas Esp Psiquiatr; 2005; 33(1):13-8. PubMed ID: 15704026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.